Kidney Transplant Infection Clinical Trial
Official title:
Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients
Cytomegalovirus (CMV) establishes a chronic infection in 60% of the general population. In renal transplant recipients, it is responsible for morbidities occurring mainly in the first 6 months after transplantation. These include viral reactivations linked to immunosuppressive treatment inhibiting the anti-CMV T lymphocyte response. CMV infection, a sign of uncontrolled viral replication, is defined by the detection of viral DNA in the peripheral blood (DNAemia). CMV disease is defined as the association of an infection and symptoms attributable to the virus. In transplant recipients carrying the virus before transplantation (positive serology: CMV+), two infection prevention strategies are recommended: either close monitoring of DNAemia with antiviral treatment in the event of positive detection (pre-emptive strategy), or antiviral treatment for the first 3 months following the transplant (prophylactic strategy). Both strategies result in the occurrence of CMV infection in 15 to 20% of patients within the first 6 months, with the majority of events occurring between 3 and 6 months. Numerous studies show that the evaluation of the anti-CMV T lymphocyte response, either before (D0) or early after transplantation (D15), or when antiviral prophylaxis is stopped, allows the identification of patients at risk of CMV infection. No study has yet demonstrated the contribution of such an evaluation in a preventive strategy. We therefore propose such a study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02439957 -
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
|
Phase 3 | |
| Not yet recruiting |
NCT06364618 -
Use of Wearables to Detect Infections in Kidney Transplant Recipients
|
||
| Completed |
NCT05142748 -
Study of Pulmonary Infections (Pneumonia) in Kidney Transplant Recipients Admitted to Hospital
|
||
| Terminated |
NCT05747053 -
Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
|
||
| Completed |
NCT03339661 -
Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T Cells Immunomonitoring.
|
Phase 2 | |
| Enrolling by invitation |
NCT05224583 -
Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant
|
||
| Recruiting |
NCT04701528 -
Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients
|
Phase 2 | |
| Recruiting |
NCT04494776 -
SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study
|
||
| Completed |
NCT02263703 -
Immunogenicity of HPV Vaccine in Immunosuppressed Children
|
Phase 3 | |
| Recruiting |
NCT06219616 -
Prediction of BK Virus Reactivation in Kidney Transplant Recipient
|
N/A | |
| Not yet recruiting |
NCT05708534 -
Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.
|
||
| Recruiting |
NCT03488771 -
Evaluation of Cell-mediated Immune Response by QuantiFERON Monitor® Assay in Kidney Transplant Recipients
|
||
| Recruiting |
NCT04815954 -
Early vs Late Urinary Catheter Removal After Renal Transplantation
|
N/A | |
| Recruiting |
NCT05727709 -
Dynamic Changes of Torquetenovirus (TTV) Load in Chinese Renal Transplant Recipients
|
||
| Completed |
NCT04542954 -
Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East
|
||
| Active, not recruiting |
NCT03924219 -
CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
|
||
| Recruiting |
NCT05836636 -
Immune Monitoring of Prevalent Kidney Transplant Recipients Using Torque Teno Virus: A Single-Center, Prospective Cohort Study
|
||
| Not yet recruiting |
NCT06407232 -
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
|
Phase 3 | |
| Completed |
NCT03468478 -
Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation
|
Phase 4 | |
| Recruiting |
NCT05397821 -
Pediatric Kidney Transplantation, Ureteroneocystostomy Techniques
|